VALIDATION OF MR TECH OF THERAPEUTIC EFFICACY FOR DRUG DISCOV IN ALZH DISEASE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 阿尔茨海默氏病（AD）在未来几年将成为所有工业化国家面临的主要公共卫生问题之一。尚未证明任何疾病改善治疗在人类中是有效和安全的。然而，在发现用于人类的潜在疾病修饰疗法中的限速步骤是缺乏在疾病的动物模型中测试药物的有效的非侵入性方法。本伙伴关系项目的重点是弥合这一差距。 在该项目中，采用体内MRMI作为斑块负荷的量度和体内MRS作为代谢物变化的量度来测量阿尔茨海默氏淀粉样斑块预防和减少的药物发现研究中的治疗功效。通过使用AD的被动免疫来测试测量治疗功效的能力。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Alzheimer's disease (AD) is poised to become one of the major public health problems facing all industrialized nations in the coming years. No disease modifying treatment has yet been proven to be efficacious and safe in humans. A rate limiting step in discovery of potential disease modifying therapies for humans however is the absence of effective non-invasive methods of testing drugs in animal models of the disease. The focus of this Partnership project is to bridge that gap. In this project, in vivo MRMI as a measure of plaque burden and in vivo MRS as a measure of metabolite changes are employed to measure therapeutic efficacy in drug discovery studies of Alzheimer's amyloid plaque prevention and reduction. The ability to measure therapeutic efficacy is tested by using passive immunization of the AD